title: Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection.
abstract: BACKGROUND
  Foot-and-mouth disease (FMD) has severe implications for animal farming which leads to considerable financial losses because of its rapid spread, high morbidity and loss of productivity. For these reasons, the use of vaccine is often favoured to prevent and control FMD. Selection of the proper vaccine is extremely difficult because of the antigenic variation within FMDV serotypes. The aim of the current study was to produce a panel of mAbs and use it for the characterization of new isolates of FMDV serotype O.
  
  
  RESULTS
  A panel of FMDV/O specific mAb was produced. The generated mAbs were then characterized using the peptide array and mAb resistant mutant selection. Seven out of the nine mAbs reacted with five known antigenic sites, thus the other two mAbs against non-neutralizing sites were identified. The mAbs were then evaluated by antigenic ELISA for the detection of forty-six FMDV serotype O isolates representing seven of ten known topotypes. Isolates ECU/4/10 and HKN/2/11 demonstrated the highest antigenic variation compared to the others. Furthermore, the panel of mAbs was used in vaccine matching by antigenic profiling ELISA with O1/Manisa as the reference strain. However, there was no correlation between vaccine matching by antigenic ELISA and the gold standard method, virus neutralisation test (VNT), for the forty-six FMDV/O isolates. Nine isolates had particularly poor correlation with the reference vaccine strain as revealed by the low r1 values in VNT. The amino acid sequences of the outer capsid proteins for these nine isolates were analyzed and compared with the vaccine strain O1/Manisa. The isolate ECU/4/10 displayed three unique amino acid substitutions around the antigenic sites 1, 3 and 4.
  
  
  CONCLUSIONS
  The panel of mAbs is useful to monitor the emergence of antigenically different strains and determination of relevant antigenic site differences. However, for vaccine matching VNT remains the preferred method but a combination of VNT, antigenic profiling with a panel of mAbs and genetic sequencing would probably be more ideal for full characterization of any new outbreak isolates as well as for selection of vaccine strains from FMDV antigen banks.
authors.affiliation: National Centre for Foreign Animal Disease, 1015 Arlington Street, Winnipeg R3E 3 M4, Manitoba, Canada. Ming.Yang@inspection.gc.ca.
authors.forename: Ming
authors.initials: M
authors.lastname: Yang
authors.forename: Wanhong
authors.initials: W
authors.lastname: Xu
authors.forename: Melissa
authors.initials: M
authors.lastname: Goolia
authors.forename: Zhidong
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000378:metabolism; D057134:Antibodies, Neutralizing / Q000276:immunology; D000940:Antigenic Variation / Q000276:immunology*; D000956:Antigens, Viral / Q000737:chemistry / Q000276:immunology*; D001666:Binding Sites, Antibody; D036022:Capsid Proteins / Q000737:chemistry / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology / Q000378:metabolism; D005260:Female; D005536:Foot-and-Mouth Disease / Q000517:prevention & control; D029544:Foot-and-Mouth Disease Virus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009154:Mutation; D009500:Neutralization Tests; D011485:Protein Binding / Q000276:immunology; D011487:Protein Conformation; D016415:Sequence Alignment; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000956:Antigens, Viral; D036022:Capsid Proteins; D000939:Epitopes; D014765:Viral Vaccines
references.citation: J Virol. 1992 Jun;66(6):3368-72
references.pmid: 1374806
references.citation: J Hyg (Lond). 1978 Aug;81(1):107-23
references.pmid: 211160
references.citation: J Virol Methods. 2008 Feb;147(2):265-74
references.pmid: 18006085
references.citation: Arch Virol. 1988;99(3-4):237-42
references.pmid: 2453185
references.citation: Vet J. 2011 Apr;188(1):18-23
references.pmid: 20350828
references.citation: Rev Sci Tech. 2005 Dec;24(3):981-93
references.pmid: 16642769
references.citation: Biologicals. 1991 Oct;19(4):299-310
references.pmid: 1665700
references.citation: J Immunol Methods. 1992 Dec 8;156(2):255-65
references.pmid: 1474260
references.citation: J Biol Stand. 1984 Jul;12(3):323-37
references.pmid: 6207176
references.citation: Vet Microbiol. 2009 Jan 13;133(3):239-51
references.pmid: 18774662
references.citation: Vaccine. 1988 Oct;6(5):403-8
references.pmid: 2848376
references.citation: J Comput Chem. 2004 Oct;25(13):1605-12
references.pmid: 15264254
references.citation: J Immunol Methods. 2007 Apr 10;321(1-2):174-81
references.pmid: 17320098
references.citation: Vaccine. 2004 Oct 22;22(31-32):4149-62
references.pmid: 15474705
references.citation: Science. 1985 Mar 22;227(4693):1435-41
references.pmid: 2983426
references.citation: J Virol. 2002 Feb;76(3):935-41
references.pmid: 11773368
references.citation: Rev Sci Tech. 1993 Jun;12(2):369-83
references.pmid: 7691272
references.citation: Virology. 1987 Apr;157(2):516-25
references.pmid: 2435060
references.citation: J Gen Virol. 2012 Mar;93(Pt 3):488-493
references.pmid: 22158876
references.citation: J Gen Virol. 1989 Mar;70 ( Pt 3):625-37
references.pmid: 2543752
references.citation: Vet Microbiol. 2012 Aug 17;158(3-4):405-9
references.pmid: 22445197
references.citation: Vaccine. 1995 Aug;13(12):1064-75
references.pmid: 7491813
references.citation: Vet Immunol Immunopathol. 2007 Jan 15;115(1-2):126-34
references.pmid: 17109972
references.citation: Can J Microbiol. 1977 Mar;23(3):295-9
references.pmid: 192426
references.citation: Biologist (London). 2001 Apr;48(2):55
references.pmid: 11313528
references.citation: Biologicals. 1990 Oct;18(4):315-9
references.pmid: 2178351
references.citation: J Gen Virol. 1989 Jun;70 ( Pt 6):1483-91
references.pmid: 2471811
references.citation: Can Vet J. 2002 May;43(5):349-54
references.pmid: 12001500
references.citation: Vet Microbiol. 2008 Jan 1;126(1-3):40-50
references.pmid: 17689892
references.citation: Virology. 1990 Nov;179(1):26-34
references.pmid: 1699353
references.citation: Vaccine. 2009 Jan 29;27(5):741-7
references.pmid: 19041355
references.citation: Vaccine. 2011 Feb 24;29(10):1906-12
references.pmid: 21236232
references.citation: Vet Microbiol. 1992 Feb;30(2-3):99-112
references.pmid: 1313624
references.citation: J Gen Virol. 1992 Dec;73 ( Pt 12):3307-11
references.pmid: 1335031
references.citation: Virus Res. 1995 Sep;38(1):1-24
references.pmid: 8546007
references.citation: J Gen Virol. 1987 Jun;68 ( Pt 6):1637-47
references.pmid: 2438378
references.citation: J Virol. 1992 Apr;66(4):1835-40
references.pmid: 1312607
references.citation: Biochemistry (Mosc). 2010 Dec;75(13):1584-605
references.pmid: 21417996
references.citation: Vaccine. 2011 Oct 26;29(46):8230-40
references.pmid: 21911020
references.citation: J Hyg (Lond). 1978 Feb;80(1):31-42
references.pmid: 202650
references.citation: Vaccine. 2010 Aug 31;28(38):6235-41
references.pmid: 20643090
references.citation: Immunology. 1986 Jul;58(3):421-8
references.pmid: 3015780
references.citation: Nucleic Acids Res. 1983 Jul 11;11(13):4629-34
references.pmid: 6866775
references.citation: Arch Virol. 2012 Oct;157(10):1967-70
references.pmid: 22707045
references.citation: J Gen Virol. 2002 Apr;83(Pt 4):775-782
references.pmid: 11907326
references.citation: J Virol. 2003 Aug;77(16):8633-9
references.pmid: 12885881
references.citation: J Gen Virol. 1993 Aug;74 ( Pt 8):1547-53
references.pmid: 8393912
references.citation: J Gen Virol. 1998 Jul;79 ( Pt 7):1687-97
references.pmid: 9680132
references.citation: Virology. 1998 Jul 20;247(1):51-61
references.pmid: 9683571
references.citation: Nature. 1993 Apr 8;362(6420):566-8
references.pmid: 8385272